Literature DB >> 19156234

The cardioprotective role of preinfarction angina as shown in outcomes of patients after first myocardial infarction.

Zorica T Mladenovic1, Andjelka Angelkov-Ristic, Dragan Tavciovski, Zdravko Mijailovic, Branko Gligic, Zoran Cosic.   

Abstract

This prospective study evaluated the relationship between preinfarction angina (2 months before a 1st acute myocardial infarction) and the extent of postinfarction myocardial injury, myocardial perfusion, contractile function, and late recovery of global left ventricular contractile function. We enrolled 46 patients who had been admitted for a 1st, single-vessel-disease, acute myocardial infarction. Low-dose dobutamine echocardiography and technetium-99m-tetrofosmin scintigraphy were performed on all patients 7 to 10 days after acute myocardial infarction; and resting echocardiography was performed 7 to 12 months later. Twenty-seven of 46 (58.7%) patients had experienced angina before acute myocardial infarction, and 19 of 46 (41.3%) had not. There was no difference between the 2 groups in acute basal left ventricular ejection fraction (P=0.17) or in basal wall motion score index (P=0.521). The maximal creatine kinase-MB level was lower in the preinfarction-angina group (P=0.039). Patients with preinfarction angina had significantly more myocardial segments with preserved regional contractile function (P <0.0001) and significantly fewer segments with less than 50% perfusion (P=0.008). Stepwise regression analysis identified preinfarction angina (r2=0.317, P=0.032) as a significant predictor of the percentage of left ventricular ejection fraction recovery after the follow-up period. In our study, preinfarction angina was associated with decreased infarct size and with better protection of global and regional left ventricular contractility and improved preservation of the microvasculature. A history of preinfarction angina should be of value in predicting the late clinical outcomes of patients after a 1st acute myocardial infarction.

Entities:  

Keywords:  Angina, unstable; angina pectoris; collateral circulation; coronary circulation; ischemic preconditioning, myocardial; myocardial contraction; myocardial infarction; myocardial ischemia; stroke volume

Mesh:

Substances:

Year:  2008        PMID: 19156234      PMCID: PMC2607100     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  27 in total

Review 1.  Coronary collateral circulation--its development and function.

Authors:  T Kanazawa
Journal:  Jpn Circ J       Date:  1994-03

2.  Protection against infarction afforded by preconditioning is mediated by A1 adenosine receptors in rabbit heart.

Authors:  G S Liu; J Thornton; D M Van Winkle; A W Stanley; R A Olsson; J M Downey
Journal:  Circulation       Date:  1991-07       Impact factor: 29.690

3.  Progressive decreases in coronary vein flow during reperfusion in acute myocardial infarction: clinical documentation of the no reflow phenomenon after successful thrombolysis.

Authors:  K Komamura; M Kitakaze; K Nishida; M Naka; J Tamai; M Uematsu; Y Koretsune; S Nanto; M Hori; M Inoue
Journal:  J Am Coll Cardiol       Date:  1994-08       Impact factor: 24.094

4.  Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?

Authors:  R A Kloner; T Shook; K Przyklenk; V G Davis; L Junio; R V Matthews; S Burstein; M Gibson; W K Poole; C P Cannon
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

5.  Myocardial perfusion imaging with 99mTc tetrofosmin. Comparison to 201Tl imaging and coronary angiography in a phase III multicenter trial. Tetrofosmin International Trial Study Group.

Authors:  B L Zaret; P Rigo; F J Wackers; R C Hendel; S H Braat; A S Iskandrian; B S Sridhara; D Jain; R Itti; A N Serafini
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

6.  Prodromal angina limits infarct size. A role for ischemic preconditioning.

Authors:  F Ottani; M Galvani; D Ferrini; F Sorbello; P Limonetti; D Pantoli; F Rusticali
Journal:  Circulation       Date:  1995-01-15       Impact factor: 29.690

7.  Ultrastructural evidence of increased tolerance of hibernating myocardium to cardioplegic ischemia-reperfusion injury.

Authors:  José Milei; César G Fraga; Daniel R Grana; Ricardo Ferreira; Giuseppe Ambrosio
Journal:  J Am Coll Cardiol       Date:  2004-06-16       Impact factor: 24.094

8.  Preconditioning protects coronary arteriolar endothelium from ischemia-reperfusion injury.

Authors:  D V DeFily; W M Chilian
Journal:  Am J Physiol       Date:  1993-08

9.  Ischemic preconditioning protects against coronary endothelial dysfunction induced by ischemia and reperfusion.

Authors:  V Richard; N Kaeffer; C Tron; C Thuillez
Journal:  Circulation       Date:  1994-03       Impact factor: 29.690

10.  Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling.

Authors:  Scott D Solomon; Nagesh S Anavekar; Sally Greaves; Jean L Rouleau; Charles Hennekens; Marc A Pfeffer
Journal:  J Am Coll Cardiol       Date:  2004-05-05       Impact factor: 24.094

View more
  3 in total

1.  Mortality implications of angina and blood pressure in hypertensive patients with coronary artery disease: New data from extended follow-up of the International Verapamil/Trandolapril Study (INVEST).

Authors:  David E Winchester; Rhonda M Cooper-Dehoff; Yan Gong; Eileen M Handberg; Carl J Pepine
Journal:  Clin Cardiol       Date:  2013-05-29       Impact factor: 2.882

Review 2.  Opportunities and challenges of pain-related myocardial ischemia-reperfusion injury.

Authors:  Wenhua Jiang; Yue Yin; Xiaoming Gu; Zihui Zhang; Heng Ma
Journal:  Front Physiol       Date:  2022-09-02       Impact factor: 4.755

3.  Association between clinical presentations before myocardial infarction and coronary mortality: a prospective population-based study using linked electronic records.

Authors:  Emily Herrett; Krishnan Bhaskaran; Adam Timmis; Spiros Denaxas; Harry Hemingway; Liam Smeeth
Journal:  Eur Heart J       Date:  2014-07-19       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.